Exclusive Networks Acquires Nuaware to Accelerate Cloud and DevOps Opportunities for Channel and Vendor Partners
24.11.2020 11:00:00 EET | Business Wire | Press release
Exclusive Networks today announced the acquisition of Nuaware, a hyper growth, born-in-the-cloud distributor at the bleeding edge of cloud, DevSecOps and containerisation. The move adds immediate global scale and services capability to the Nuaware proposition and portfolio, while enabling Exclusive Networks, its vendors and partner community with a unique skill set for capitalising on immense demand shifts brought about by digital transformation.
Jesper Trolle, CEO at Exclusive Networks said: "DevOps tool chains, containers and the emergence of DevSecOps are specialist areas where Nuaware has carved a truly unique niche in distribution. This acquisition puts us where we want to be in this space, giving our partners a readymade on-ramp into new high-growth opportunities. Large vendors being drawn to these markets are seeking turnkey channel solutions, and their established partner ecosystems have technical skills gaps that demand credible support. We can now meet these kinds of challenges far more effectively, while continuing to accelerate growth for the next waves of disruptive technologies in secure, trusted digital infrastructure.”
Nuaware was founded in 2016 by Zaheer Javaid and Luke Hasty and has grown exponentially since then through its work with vendors including HashiCorp, Docker Enterprise (now Mirantis), Instana, Portworx (recently acquired by Pure Storage) and Twistlock (now Palo Alto Networks Prisma Cloud). The company's London-based team, which works with both large service providers/systems integrators and a network of specialist DevOps consultancies on implementations around the world, will carry on operating as a distinct business unit under the Nuaware brand and continue to target disruptive new technologies and partnerships with emerging high-growth vendors such as, for example, Gremlin and StackPulse in areas such as chaos engineering and SRE automation. Its high-value services, including lead detection, business development, solution design, implementation, professional services and comprehensive training courses, will complement those from Exclusive Networks and vice versa.
Zaheer Javaid, Co-Founder and Director at Nuaware said: “We’re very pleased to be joining the Exclusive family and believe this is the best way to continue scaling up our proposition and bringing optimum value to all our customers and partners. The timing is right – the rapid onset of digital transformation among enterprises has got much faster in 2020, bringing Nuaware and the DevOps, cloud automation and containerisation technologies we specialise in, to an inflection point. With Exclusive’s support, we can aim higher, grow faster and invest more in extending our uniqueness in the market.”
“In terms of culture, attitude to innovation and the capacity to create unique value in the context of technology and market disruption, Nuaware is very much like Exclusive Networks,” said Andy Travers, EVP Worldwide Sales and Marketing at Exclusive Networks. “Teaming up this way is great news for partners of both companies, including the strategic vendors we have in common: Palo Alto Networks and Pure Storage. We anticipate significant organic growth from the Nuaware business by supporting its plans for continued expansion globally, and see many additional commercial benefits from extending their know-how across and into more opportunities with Exclusive Networks vendors and resellers.”
-ends-
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005189/en/
Contact information
Exclusive Networks Contact:
Jemma Lowman
Cohesive
+44 (0) 1291 626200
exclusivegroup@wearecohesive.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
